Cwestiynau Ysgrifenedig y Cynulliad a gyflwynwyd ar 28 Tachwedd 2014 i'w hateb ar 5 Rhagfyr 2014
R - Yn dynodi bod yr Aelod wedi datgan buddiant.
W - Yn dynodi bod y cwestiwn wedi'i gyflwyno yn Gymraeg.
(Dangosir rhif gwreiddiol y Cwestiwn mewn cromfachau)
Rhaid cyflwyno Cwestiynau Ysgrifenedig o leiaf bum diwrnod gwaith cyn y disgwylir iddynt gael eu hateb. Yn ymarferol, bydd Gweinidogion yn ceisio ateb o fewn saith neu wyth diwrnod ond nid oes rheidrwydd arnynt i wneud hynny. Cyhoeddir yr atebion unwaith iddynt gael eu derbyn yn yr iaith y'u cyflwynir ynddi, gyda chyfieithiad i'r Saesneg o ymatebion a roddir yn y Gymraeg.
Gofyn i'r Gweinidog Iechyd a Gwasanaethau Cymdeithasol
Kirsty Williams (Brycheiniog a Sir Faesyfed): Pa gynnydd sy'n cael ei wneud mewn perthynas ag ariannu gwasanaethau clefyd yr ysgyfaint gwagleol yn ffurfiol yng Nghymru? (WAQ68073)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol (Mark Drakeford): In 2013, NICE issued both a health technology assessment (TA262) and a clinical guideline on the treatment of Idiopathic Pulmonary Fibrosis (CG163). Health boards have considered these locally and through the All Wales Medical Directors Group. The development of a single coordinated specialized MDT approach has been identified as the best method to implement the guidance. This would increase equity and is likely to improve outcomes and manage demand. WHSSC will be facilitating discussions to put this in place.
Kirsty Williams (Brycheiniog a Sir Faesyfed): Faint o nyrsys sy'n arbenigo yn ffibrosis yr ysgyfaint idiopathig sydd wedi'u lleoli yng Nghymru ar hyn o bryd, a pha gamau sy'n cael eu cymryd i gynyddu ymwybyddiaeth a diagnosis o'r cyflwr? (WAQ68074)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Mark Drakeford: We do not hold figures on the number of specialist IPF nurses. Health boards are required to ensure that - as with lung cancer - patients are managed through a multi-disciplinary team, made up of doctors, nurses and experts in the condition, and have access to specialist nursing support.
Health boards are working together to develop a national approach to treating IPF in line with National Institute for Health and Care Excellence guidelines and the ambitions set out in our Respiratory Delivery Plan.
Darren Millar (Gorllewin Clwyd): Pa gamau y mae Llywodraeth Cymru yn eu cymryd i godi ymwybyddiaeth o hepatitis C a gwella diagnosis a thriniaeth o'r clefyd ymysg grwpiau sydd mewn perygl, gan gynnwys: i) y gymuned de-Asiaidd; ii) pobl sy'n chwistrellu cyffuriau (gan gynnwys y rhai sy'n chwistrellu cyffuriau sy'n gwella delwedd); iii) cleifion a gontractiodd y clefyd drwy ddod i gysylltiad â chynnyrch gwaed halogedig; a iv) pobl ddigartref? (WAQ68075)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Mark Drakeford: In August 2014, the Chief Medical Officer for Wales wrote to the NHS regarding arrangements for identifying and referring patients with Hepatitis C or Hepatitis B virus. The letter brings together a range of information to raise awareness of hepatitis infection in at risk groups to assist GPs and healthcare professionals to improve patient services. A copy of the letter can be found at:
http://wales.gov.uk/topics/health/cmo/publications/cmo/2014/hepatitis/?lang=en
Since the introduction of the Blood Borne Viral Hepatitis Action Plan for Wales in 2010, over 100 individuals in Wales working with groups at risk of infection have completed the Royal College of General Practitioners' course on blood borne viral hepatitis. A "train the trainer" course on blood borne viruses was rolled out in 2011 and over 100 individuals from a range of organisations including those from health care, prisons and local authorities have been trained to provide further training within their organisations.
The clinical networks set up under the Blood Borne Viral Hepatitis Action Plan have established links with a range of local agencies to help raise awareness. These include third sector organisations, statutory and non-statutory substance misuse services and housing services.
Darren Millar (Gorllewin Clwyd): Pa gamau sy'n cael eu cymryd gan Lywodraeth Cymru i sicrhau y gellir darparu gwasanaethau ymwybyddiaeth, diagnosis a thriniaeth ar gyfer hepatitis C mewn lleoliadau priodol i'r claf (hynny yw, mewn clinigau hemoffilia, hosteli digartref, canolfannau cyffuriau ac alcohol, ac yn y gymuned)? (WAQ68076)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Y Gweinidog Iechyd a Gwassanethau Cymdeithasol (Mark Drakeford): Funding from the Welsh Government in 2013 enabled Health Boards to purchase an additional five specialist scanners which can detect liver damage without the need for invasive biopsies. All Health Boards in Wales with a hepatitis treatment centre now have access to both a fixed and portable scanner. Portable scanners can be used at a range of outreach centres to improve diagnosis and services for harder to reach groups who may not otherwise attend clinics.
Darren Millar (Gorllewin Clwyd): Yn dilyn cyhoeddi'r strategaeth afu, pa gyllid y mae Llywodraeth Cymru yn ei ddarparu i sicrhau bod cleifion yn gallu manteisio ar ddatblygiadau o ran trin hepatitis C? (WAQ68077)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Mark Drakeford: Provision has been made within the draft budget for 2015-2016 to maintain support for the clinical networks established through the Blood Borne Viral Hepatitis Action Plan. The costs of meeting any new hepatitis treatments approved by National institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group will be taken into account when setting the annual allocation and consequent efficiency requirements for the NHS.
Darren Millar (Gorllewin Clwyd): Pa asesiad y mae Llywodraeth Cymru wedi'i wneud o effaith y triniaethau newydd ar gyfer hepatitis C yng Nghymru? (WAQ68078)
Derbyniwyd ateb ar 8 Rhagfyr 2014
Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol (Mark Drakeford): Innovation in the development of new drugs and treatments is the key factor in reducing the burden of hepatitis C infection. The ongoing advances in treatments for hepatitis C provide the potential for much improved patient outcomes.
There are established processes for the introduction of new treatments into the NHS in Wales. The Welsh Government is monitoring progress on the National Institute of Health and Care Excellence's (NICE) appraisal of new hepatitis C treatments and will consider the implications when guidance is available. Health boards must make any medicines available that have been recommended for routine use by NICE or the All Wales Medicines Strategy Group no later than three months following their decision.